1. Rostami-Moez M, Masoumi SZ, Otogara M, Farahani F, Alimohammadi S, Oshvandi K. Examining the health-related needs of females during menopause: a systematic review study.J Menopausal Med. 2023;29(1):1-20. doi:10.6118/jmm.22033
2. Uzun S, Ozcan H, Jones D. The psychological dimension of menopause: a phenomenological study: being menopause in Turkiye: a qualitative study. Curr Psychol. 2023;42(13):10498-507.
3. Habeeb S. Menopause: transition, effects, and methods. in: encyclopedia of sexual psychology and behavior. Springer. 2023. p. 1-12. Zhang S, Huang X, Zhao X, et al. Effect of exercise on bone mineral density among patients with osteoporosis and osteopenia: a systematic review and network meta-analysis.J Clin Nurs. 2022;31(15-16):2100-2111. doi:10.1111/jocn.16101
4. Zhang S, Huang X, Zhao X, et al. Effect of exercise on bone mineraldensity among patients with osteoporosis and osteopenia: a systematicreview and network meta-analysis.J Clin Nurs. 2022;31(15-16):2100-2111.doi:10.1111/jocn.16101
5. Watts NB, Binkley N, Owens CD, et al. Bone mineral density changes associated with pregnancy, lactation, and medical treatments in premenopausal women and effects later in life.J Womens Health (Larchmt). 2021;30(10):1416-1430. doi:10.1089/jwh.2020.8989
6. Kolodziejska B, Stepien N, Kolmas J. The influence of strontium on bone tissue metabolism and its application in osteoporosis treatment.Int J Mol Sci. 2021;22(12):6564. doi:10.3390/ijms22126564
7. Bonnick SL. Osteoporosis in men and women.Clin Cornerstone. 2006;8(1):28-39. doi:10.1016/s1098-3597(06)80063-3
8. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis.Eur J Rheumatol. 2017;4(1):46-56. doi:10.5152/eurjrheum. 2016.048
9. Dimai HP, Fahrleitner-Pammer A. Osteoporosis and fragility fractures: currently available pharmacological options and future directions.Best Pract Res Clin Rheumatol. 2022;36(3):101780. doi:10.1016/j.berh.2022.101780
10. Dempster DW. Osteoporosis and the burden of osteoporosis-related fractures.Am J Manag Care. 2011;17 (Suppl 6):S164-S169.
11. Tuzun S, Eskiyurt N, Akarirmak U, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study.Osteoporos Int. 2012;23(3):949-955. doi:10.1007/s00198-011-1655-5
12. Keskin Y, Cekin Md, Gündüz H, et al. The prevalence of osteoporosis in the thrace region of Turkey: a community-based study. Turk J Phys Med Rehabil Fiz Tip Ve Rehabil Derg. 2014;60(4):335-340
13. Rajaraman R, Vaithilingan S, Selvavinayagam TS. Acceptance, adherence, and side effects of depot medroxyprogesterone acetate: a prospective observational study.Cureus. 2024;16(4):e58700. doi:10.7759/cureus.58700
14. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.Contraception. 2008;77(2):67-76. doi:10.1016/j.contraception.2007.10.005
15. Roksvaag I, Skjeldestad FE. Decreasing trends in number of depot medroxyprogesterone acetate starters in Norway - a cross-sectional study. Acta Obstet Gynecol Scand. 2018;97(2):151-157. doi:10.1111/aogs. 13262
16. Kaunitz AM. Depot medroxyprogesterone acetate (DMPA): efficacy, side effects, metabolic impact, and benefits. UpToDate Accessed March 23 2023 Dispon En Httpswww Uptodate Comcontentsdepot-Medroxyprogesteroneacetate-Dmpa-Effic-Side-Eff-Metab-Impact--Benefits. 2022;
17. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate.Fertil Steril. 2004;82(6):1580-1586. doi:10.1016/j.fertnstert.2004.04.064
18. Harel Z, Johnson CC, Gold MA, et al. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections.Contraception. 2010;81(4):281-291. doi:10.1016/j.contraception.2009.11.003
19. Beksinska ME. Bone mineral density and use of depot medroxyprogesterone acetate (DMPA), norethisterone enanthate (NET-EN) and combined oral contraceptives. 2010;
20. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception.Obstet Gynecol. 1999;93(2):233-238. doi:10.1016/s0029-7844(98)00447-5
21. Ebeisy HAEHE, Mahmoud NE, Kandeel HT, Tawwab SMSE. Bone mineral density among long term users of hormonal contraception (Contraception & Bone mineral density). Al-Azhar Int Med J. 2024;5(2):25.
22. Cheng CH, Chen LR, Chen KH. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover.Int J Mol Sci. 2022;23(3):1376. doi:10.3390/ijms 23031376.
23. Rajan R, Paul J, Kapoor N, Cherian KE, Paul TV. Postmenopausal osteoporosis-an Indian perspective. Curr Med Issues. 2020;18(2):98-104.
24. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.Am J Med. 1991; 90(2):171-178.
25. Viola AS, Castro S, Marchi NM, Bahamondes MV, Viola CF, Bahamondes L. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.Contraception. 2011;84(2):122-127. doi:10.1016/j.contraception.2010.11.007
26. Viola AS, Castro S, Bahamondes MV, Fernandes A, Viola CF, Bahamondes L. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate. Contraception. 2011;84(5):e31-e37. doi:10. 1016/j.contraception.2011.06.012
27. Sanches L, Marchi NM, Castro S, Juliato CT, Villarroel M, Bahamondes L. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate [published correction appears in Contraception. 2009 79(2):159-60].Contraception. 2008;78(5):365-369. doi:10.1016/j.contraception.2008.07.013
28. Modesto W, Bahamondes MV, Bahamondes L. Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate.J Womens Health (Larchmt). 2015;24(8):636-640. doi:10.1089/jwh.2014.5077